146 related articles for article (PubMed ID: 9106004)
1. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis.
Schmahl KS; Ganjoo AK; Harloff MG
J Cardiothorac Vasc Anesth; 1997 Apr; 11(2):262-3. PubMed ID: 9106004
[No Abstract] [Full Text] [Related]
2. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.
Grocott HP; Root J; Berkowitz SD; deBruijn N; Landolfo K
J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):875-7. PubMed ID: 9412888
[No Abstract] [Full Text] [Related]
3. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia.
Insler SR; Kraenzler EJ; Bartholomew JR; Kottke-Marchant K; Lytle B; Starr NJ
Anesthesiology; 1997 Feb; 86(2):495-8. PubMed ID: 9054269
[No Abstract] [Full Text] [Related]
4. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
5. [Thrombopenia increased by heparin and danaparoid].
Godet G; Bertrand M; Van de Steen E; Boccara G; Koskas F
Ann Fr Anesth Reanim; 2001 Jan; 20(1):50-3. PubMed ID: 11234580
[TBL] [Abstract][Full Text] [Related]
6. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
Murphy GS; Marymont JH
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
[No Abstract] [Full Text] [Related]
7. [Current treatment concepts in heparin-induced thrombocytopenia].
Ranze O; Greinacher A
Dtsch Med Wochenschr; 1999 Jul; 124(28-29):865-73. PubMed ID: 10432950
[No Abstract] [Full Text] [Related]
8. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172.
Wilhelm MJ; Schmid C; Kececioglu D; Möllhoff T; Ostermann H; Scheld HH
Ann Thorac Surg; 1996 Mar; 61(3):920-4. PubMed ID: 8619718
[TBL] [Abstract][Full Text] [Related]
9. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
Olin DA; Urdaneta F; Lobato EB
J Cardiothorac Vasc Anesth; 2000 Dec; 14(6):707-9. PubMed ID: 11139115
[No Abstract] [Full Text] [Related]
10. [Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy].
Tardy-Poncet B; Reynaud J; Tardy B; Mahul P; Mismetti P; Beraud AM; Rebaud MA; Bayon M; Guyotat D
Presse Med; 1996 May 4-11; 25(16):751-5. PubMed ID: 8692750
[TBL] [Abstract][Full Text] [Related]
11. Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.
Burkhard-Meier U; Söhngen D; Schultheiss HP; Greinacher A; Schwartzkopff B; Vogt M; Heyll A; Schneider W
Intensive Care Med; 1995 Jun; 21(6):542-3. PubMed ID: 7560499
[No Abstract] [Full Text] [Related]
12. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
Gillis S; Merin G; Zahger D; Deeb M; Drenger B; Hyam E; Eldor A
Br J Haematol; 1997 Sep; 98(3):657-9. PubMed ID: 9332322
[TBL] [Abstract][Full Text] [Related]
13. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).
Ramakrishna R; Manoharan A; Kwan YL; Kyle PW
Br J Haematol; 1995 Nov; 91(3):736-8. PubMed ID: 8555084
[TBL] [Abstract][Full Text] [Related]
14. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
[TBL] [Abstract][Full Text] [Related]
15. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
[No Abstract] [Full Text] [Related]
16. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
Dworschak M; Hiesmayr JM; Lassnigg A
Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
[TBL] [Abstract][Full Text] [Related]
17. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).
Saxon BR; Black MD; Edgell D; Noel D; Leaker MT
Ann Thorac Surg; 1999 Sep; 68(3):1076-8. PubMed ID: 10510017
[TBL] [Abstract][Full Text] [Related]
18. Heparin-induced thrombocytopenia and thrombosis.
Patel VP; Bong M; Di Cesare PE
Am J Orthop (Belle Mead NJ); 2007 May; 36(5):255-60. PubMed ID: 17571830
[TBL] [Abstract][Full Text] [Related]
19. [Bounderies of the authorization to market and the therapeutic impass].
Samama CM
Ann Fr Anesth Reanim; 2001 Jun; 20(6):507-8. PubMed ID: 11471497
[No Abstract] [Full Text] [Related]
20. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
